Coherus Biosciences

CHRS58

Penny Stock

$1.13arrow_drop_up7.61%$0.08

Penny Stock

CHRS58

$1.13

arrow_drop_up7.61%$0.08

Penny Stock

Performance History

Key Stats
Open	$1.10
Prev. Close	$1.05
EPS	-0.38
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$120.96M
PE Ratio	-

	LOW	HIGH
Day Range	1.07	1.14
52 Week Range	1.01	4.73

Ratios

Revenue	-





EPS	-0.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Coherus Biosciences (CHRS)

Now let's take a look at the stock price history for Coherus Biosciences Inc (CHRS). Coherus Biosciences Inc is a biopharmaceutical company focused on developing and commercializing biosimilar products. The company's stock price has seen some fluctuations over the years, reflecting the ups and downs of the biotech industry. However, it has generally shown a positive trend, indicating investor confidence in the company's potential. It is important to note that past performance is not necessarily indicative of future results, and the stock market can be unpredictable. Investors should carefully consider their investment goals and risk tolerance before making any decisions regarding Coherus Biosciences Inc stock.

Moving on to the quote for Coherus Biosciences Inc (CHRS), it is important for investors to stay up to date with the current stock price. The quote provides real-time information on the latest trading activity, including the bid and ask prices, as well as the volume of shares being traded. This information can be used to assess market sentiment and make informed investment decisions. It is recommended that investors regularly check the quote for Coherus Biosciences Inc stock to stay informed about the latest developments in the market.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Dennis M. Lanfear
Headquarters: Redwood City
Employees: 294
Exchange: NASDAQ

Keep an eye on Coherus Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Coherus Biosciences 's (CHRS) price per share?

The current price per share for Coherus Biosciences (CHRS) is $1.13. The stock has seen a price change of $0.08 recently, indicating a 7.62% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Coherus Biosciences (CHRS)?

For Coherus Biosciences (CHRS), the 52-week high is $4.73, which is 318.58% from the current price. The 52-week low is $1.01, the current price is 11.88% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Coherus Biosciences (CHRS) a growth stock?

Coherus Biosciences (CHRS) has shown an average price growth of 0.41% over the past three years. It has received a score of 10 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Coherus Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Coherus Biosciences (CHRS) stock price performance year to date (YTD)?

As of the latest data, Coherus Biosciences (CHRS) has a year-to-date price change of -64.01%. Over the past month, the stock has experienced a price change of -10.67%. Over the last three months, the change has been -30.25%. Over the past six months, the figure is -53.88%. Looking at a longer horizon, the five-year price change stands at -94.51%.

help

Is Coherus Biosciences (CHRS) a profitable company?

Coherus Biosciences (CHRS) has a net income of -$237.89M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 36.72% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -31.56% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 21.89%, providing insight into the company's sales performance and growth. The gross profit is $94.46M. Operating income is noted at -$193.2M. Furthermore, the EBITDA is -$142.29M.

help

What is the market capitalization of Coherus Biosciences (CHRS)?

Coherus Biosciences (CHRS) has a market capitalization of $120.97M. The average daily trading volume is 2.47M, indicating the stock's liquidity and investor engagement.

News

Hepatic Tumor Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 75+ Companies Working in the Domain

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

HEALTH

6/27/2024

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

6/23/2024

Pfizer: Seriously Undervalued At Peak Pessimism

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

CLINICAL STUDY

CALENDAR OF EVENTS

5/23/2024

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting